179 related articles for article (PubMed ID: 21489048)
1. Hallucination induced by paroxetine discontinuation in patients with major depressive disorders.
Yasui-Furukori N; Kaneko S
Psychiatry Clin Neurosci; 2011 Jun; 65(4):384-5. PubMed ID: 21489048
[TBL] [Abstract][Full Text] [Related]
2. Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome.
Murata Y; Kobayashi D; Imuta N; Haraguchi K; Ieiri I; Nishimura R; Koyama S; Mine K
J Clin Psychopharmacol; 2010 Feb; 30(1):11-7. PubMed ID: 20075642
[TBL] [Abstract][Full Text] [Related]
3. Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine.
Greist J; McNamara RK; Mallinckrodt CH; Rayamajhi JN; Raskin J
Clin Ther; 2004 Sep; 26(9):1446-55. PubMed ID: 15531007
[TBL] [Abstract][Full Text] [Related]
4. Visual and auditory hallucinations during normal use of paroxetine for treatment of major depressive disorder.
Monji A; Kato T; Mizoguchi Y; Horikawa H; Seki Y; Kanba S
J Neuropsychiatry Clin Neurosci; 2011; 23(4):E14-5. PubMed ID: 22231326
[No Abstract] [Full Text] [Related]
5. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
6. Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder.
Perahia DG; Kajdasz DK; Desaiah D; Haddad PM
J Affect Disord; 2005 Dec; 89(1-3):207-12. PubMed ID: 16266753
[TBL] [Abstract][Full Text] [Related]
7. A case with occurring adverse effects when cross-over titration from fluvoxamine to paroxetine associated with increasing the plasma fluvoxamine level in major depressive disorder.
Hori H; Yoshimura R; Ueda N; Ikenouchi-Sugita A; Umene-Nakano W; Nakamura J
World J Biol Psychiatry; 2009; 10(4 Pt 2):620-2. PubMed ID: 18609433
[TBL] [Abstract][Full Text] [Related]
8. Delirium induced by abrupt discontinuation of paroxetine.
Hayakawa Y; Sekine A; Shimizu T
J Neuropsychiatry Clin Neurosci; 2004; 16(1):119-20. PubMed ID: 14990771
[No Abstract] [Full Text] [Related]
9. Withdrawal after discontinuation of paroxetine.
Arya DK
Aust N Z J Psychiatry; 1996 Oct; 30(5):702. PubMed ID: 8902183
[No Abstract] [Full Text] [Related]
10. Adverse events after the abrupt discontinuation of paroxetine.
Dominguez RA; Goodnick PJ
Pharmacotherapy; 1995; 15(6):778-80. PubMed ID: 8602387
[TBL] [Abstract][Full Text] [Related]
11. Discontinuation syndrome associated with paroxetine in depressed patients: a retrospective analysis of factors involved in the occurrence of the syndrome.
Himei A; Okamura T
CNS Drugs; 2006; 20(8):665-72. PubMed ID: 16863271
[TBL] [Abstract][Full Text] [Related]
12. Venlafaxine withdrawal syndrome.
Sabljić V; Ružić K; Rakun R
Psychiatr Danub; 2011 Mar; 23(1):117-9. PubMed ID: 21448114
[TBL] [Abstract][Full Text] [Related]
13. Selective serotonin reuptake inhibitor. Discontinuation syndrome.
Finfgeld DL
J Psychosoc Nurs Ment Health Serv; 2002 Dec; 40(12):14-8. PubMed ID: 12491870
[TBL] [Abstract][Full Text] [Related]
14. Discontinuation symptoms in depression and anxiety disorders.
Baldwin DS; Montgomery SA; Nil R; Lader M
Int J Neuropsychopharmacol; 2007 Feb; 10(1):73-84. PubMed ID: 16359583
[TBL] [Abstract][Full Text] [Related]
15. Newer antidepressants and the discontinuation syndrome.
Haddad P
J Clin Psychiatry; 1997; 58 Suppl 7():17-21; discussion 22. PubMed ID: 9219489
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care.
Wade A; Crawford GM; Angus M; Wilson R; Hamilton L
Int Clin Psychopharmacol; 2003 May; 18(3):133-41. PubMed ID: 12702891
[TBL] [Abstract][Full Text] [Related]
17. Discontinuation syndrome in dysthymic patients treated with selective serotonin reuptake inhibitors: a clinical investigation.
Bogetto F; Bellino S; Revello RB; Patria L
CNS Drugs; 2002; 16(4):273-83. PubMed ID: 11945110
[TBL] [Abstract][Full Text] [Related]
18. Venlafaxine withdrawal reactions.
Boyd IW
Med J Aust; 1998 Jul; 169(2):91-2. PubMed ID: 9700345
[No Abstract] [Full Text] [Related]
19. Clinical application of paroxetine for tapering benzodiazepine use in non-major-depressive outpatients visiting an internal medicine clinic.
Nakao M; Takeuchi T; Nomura K; Teramoto T; Yano E
Psychiatry Clin Neurosci; 2006 Oct; 60(5):605-10. PubMed ID: 16958945
[TBL] [Abstract][Full Text] [Related]
20. Minor strokes related to paroxetine discontinuation in an elderly subject: emergent adverse events.
Ramasubbu R
Can J Psychiatry; 2003 May; 48(4):281-2. PubMed ID: 12776398
[No Abstract] [Full Text] [Related]
[Next] [New Search]
